BioTuesdays

Category - Markets

BioTime
Markets

Dawson James starts BioTime at buy; PT $6

Dawson James Securities initiated coverage of BioTime (NYSE American:BTX) with a “buy” rating and $6 price target. The stock closed at $1.16 on Feb. 6. “We view BioTime as a new company invigorated by a new management...

February 7, 2019
Marinus Pharma
Markets

SVB Leerink starts Marinus Pharma at OP; PT $10

SVB Leerink launched coverage of Marinus Pharmaceuticals (NASDAQ:MRNS) with an “outperform” rating and sum-of-the-parts price target of $10. The stock closed at $3.66 on Feb. 5. Analyst Marc Goodman writes that his...

February 6, 2019
Trevena
Markets

HCW ups Trevena PT to $1.25 from 75c

H.C. Wainwright raised its price target for Trevena (NASDAQ:TRVN) to $1.25 from 75 cents, saying that resolution on two clinical requests from the FDA paves a path for the company’s NDA resubmission for oliceridine, a...

February 5, 2019
Rexahn Pharmaceuticals
Markets

HCW cuts Rexahn Pharma PT to $10 from $17

H.C. Wainwright lowered its price target for Rexahn Pharmaceuticals (NYSE American:PNN) to $10 from $17 to reflect a higher number of shares outstanding after an equity issue in January. The stock closed at 63 cents on...

February 5, 2019
AVEO Pharmaceuticals Logo
Markets

HCW cuts AVEO Pharma to neutral; PT to $1 from $9

H.C. Wainwright downgraded AVEO Pharmaceuticals (NASDAQ:AVEO) to “neutral” from “buy” and slashed its price target to $1 from $9 after the FDA recommended against the filing of a tivozanib NDA, citing the lack of...

February 1, 2019
Mesoblast Logo
Markets

HCW assumes coverage of Mesoblast at buy; PT $6.50

H.C. Wainwright analyst Swayampakula Ramakanth assumed coverage of Mesoblast (NASDAQ:MESO) with a “buy” rating and price target of $6.50. The stock closed at $4.56 on Jan. 30. Australia-based Mesoblast is focused on...

January 31, 2019
scPharmaceuticals
Markets

Leerink cuts scPharma to MP; PT to $5 from $12

Leerink downgraded scPharmaceuticals (NASDAQ:SCPH) to “market perform” from “outperform” and slashed its price target to $5 from $12 after the company inked a deal to use West Pharmaceuticals’ SmartDose on-body drug...

January 30, 2019
Evolus
Markets

Stifel starts Evolus at buy; PT $27

Stifel launched coverage of Evolus (NASDAQ:EOLS) with a “buy” rating and 12-month price target of $27. The stock closed at $14.99 on Jan. 28. “Evolus’ success hinges on the potential for Jeuveauto serve as an...

January 29, 2019
Revance
Markets

Stifel starts Revance Therapeutics at buy; PT $50

Stifel initiated coverage of Revance Therapeutics (NASDAQ:RVNC) with a “buy” rating and $50 target price. The stock closed at $17 on Jan. 28. Revance’s Daxi product represents “one of the first truly novel neurotoxin...

January 29, 2019